Debt-to-equity of Stoke Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Stoke Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Stoke Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 16%, a 51% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Stoke Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 16% -17% -51% 30 Sep 2025
Q2 2025 18% -19% -51% 30 Jun 2025
Q1 2025 21% -19% -47% 31 Mar 2025
Q4 2024 28% -9% -25% 31 Dec 2024
Q3 2024 34% -2.3% -6.3% 30 Sep 2024
Q2 2024 37% +1.9% +5.3% 30 Jun 2024
Q1 2024 40% +5.3% +15% 31 Mar 2024
Q4 2023 37% +1.8% +5.2% 31 Dec 2023
Q3 2023 36% +7.9% +28% 30 Sep 2023
Q2 2023 35% +15% +70% 30 Jun 2023
Q1 2023 35% +22% +171% 31 Mar 2023
Q4 2022 35% +29% +545% 31 Dec 2022
Q3 2022 28% +24% +569% 30 Sep 2022
Q2 2022 21% +17% +494% 30 Jun 2022
Q1 2022 13% +9.5% +279% 31 Mar 2022
Q4 2021 5.4% +1.8% +49% 31 Dec 2021
Q3 2021 4.2% +1.2% +39% 30 Sep 2021
Q2 2021 3.5% +0.88% +34% 30 Jun 2021
Q1 2021 3.4% +1.1% +50% 31 Mar 2021
Q4 2020 3.6% 31 Dec 2020
Q3 2020 3% 30 Sep 2020
Q2 2020 2.6% 30 Jun 2020
Q1 2020 2.3% 31 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.